Patient P-02320
Therapy response
Improving
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
94%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 GI symptom burden −21% vs expected — Dietary Support Protocol NP-02
- Day 64 Tolerance state changed — Unstable → Improving
- Day 75 GI-04 recommended — GI Support Protocol GI-04
- Day 76 Patient declined — Not now
- Day 80 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 80.
Primary contributors, last 14 days
- Inflammatory activity-12
- Toxicity-8
- Nutritional resilience+5
- GI instability-4
- Treatment adherence-3
What helped?
- Dietary Support Protocol NP-02Day 47Result: symptom burden −21%
- GI Support Protocol GI-04Day 75Declined by patient
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 89% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 61
- WearableHRV 33 ms, trending down
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 65 and rising
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 34/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 50
- Autonomic recovery ↑45
- WearableResting HR 82 bpm
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 3.2 · butyrate capacity 34/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 29 ms
- Sleep
- 6.5 h
- Steps
- 3,528
- Resting HR
- 84 bpm
Daily log: GI score 65, nutritional resilience 35, adherence 46.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02348 | 60% | S14 | GI-04 | improved | 49 |
| P-02157 | 58% | S14 | ME-01 | improved | 55 |
| P-02535 | 57% | S14 | SC-12 | improved | 50 |
| P-02628 | 55% | S14 | SC-12 | improved | 47 |
| P-02594 | 53% | S20 | — | — | 45 |
| P-02118 | 51% | S14 | GI-04 | improved | 47 |
| P-02253 | 51% | S14 | NP-02 | no change | 41 |
| P-02643 | 51% | S14 | SC-12 | improved | 46 |
| P-02132 | 50% | S14 | SC-12 | improved | 40 |
| P-02363 | 50% | S14 | GI-04 | improved | 49 |
| P-02546 | 50% | S20 | NP-02 | improved | 40 |
| P-02574 | 50% | S14 | ME-01 | improved | 45 |